⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
NAVIGATE Study – Galectin Therapeutics
What this score means
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. NAVIGATE Study – Galectin Therapeutics just got measured.
5/10 means NAVIGATE Study – Galectin Therapeutics is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
About NAVIGATE Study – Galectin Therapeutics
The NAVIGATE Study clinical trial is currently the only Phase 2b/3 clinical trial focused on NASH cirrhosis, for which there are no approved therapies short of a liver transplant.
Key Topics
Details
Industry: Healthcare
navigatenash.comAI Visibility Breakdown
2
Structured Data
8
Content Structure
6
Entity Clarity
4
E-E-A-T Signals
6
Technical AEO
4
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
Trust Is the Product. AI Is How You Build It at Scale.
In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for NAVIGATE Study – Galectin Therapeutics.
Source & Attribution
Scored by Engagemii on July 2, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/navigatenash
Cite this score: Engagemii (2026). "AEO Score for NAVIGATE Study – Galectin Therapeutics." Retrieved from https://engagemii.com/aeo/brands/navigatenash
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform